The Solas team had an incredible week at LSI Europe 2025 in London. Laurent Pacheco, Isaiah Reeves, David Adair, and Joshua Eckelberry joined hundreds of leaders from across the life sciences community to connect, share ideas, and explore the future of MedTech and healthcare innovation. From thoughtful panels to meaningful conversations over dinners and networking, we are energized by the entrepreneurs, investors, and partners driving this ecosystem forward. As we move into the final quarter of 2025, we’re excited to build on the momentum from this event. Stay tuned!
Solas BioVentures
Investment Management
Chattanooga, Tennessee 1,949 followers
Not your ordinary VC. We invest in Medtech & Biotech entrepreneurs bringing seismic improvements in patient outcomes.
About us
Solas BioVentures is a venture capital firm that invests in early and development stage biopharma, medical device, diagnostics, and digital health companies.
- Website
-
http://solasbio.com
External link for Solas BioVentures
- Industry
- Investment Management
- Company size
- 2-10 employees
- Headquarters
- Chattanooga, Tennessee
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Medical Devices, Biotechnology, and Venture Capital
Locations
-
Primary
Get directions
Chattanooga, Tennessee, US
-
Get directions
Minneapolis, Minnesota, US
-
Get directions
Nashville, Tennessee, US
Employees at Solas BioVentures
-
Amy Grogg, PharmD
-
Dr. Michael Ackermann, PhD, MBA
Co-Founder, Board Member and Chief Business Officer at Arrivo BioVentures LLC
-
Lana B. Caron
Healthcare & Life Sciences Leader | AI, Digital Health, Medtech & BioPharma | Board Member & Venture Investor
-
Frank B.
Richard X. Zhang Endowed Professor of Business in the Gary W. Rollins College of Business
Updates
-
Solas BioVentures reposted this
Investor at Mercia Ventures - Investing in Life Science and Technology Companies in the UK
Brilliant couple of days at an incredibly well attended #LSIEurope25 in London representing Mercia Ventures. It was clear to see from the volume of investors in attendance that the market is starting to open up for business and that we're starting to see the green shoots of activity in the M&A market that we've all been waiting for (OrganOx's exit to Terumo Medical Corporation, for instance). It was also a pleasure to take to the stage this morning to discuss the global MedTech investment landscape with a number of experienced investors from around the world (Nick Pachuda, Bibi Sattar Marques and Branden Rosenhan MD) - well moderated C David Adair MD, MBA, FACOG, FASH, C-EFM. Thanks to all those who took the time to meet with us over the last couple of days - I'll be in touch when I've had a sleep! And thank you once again, Scott Pantel for the invite. A fantastic conference, as always. LSI #Medtech #Investment #Venture
-
-
Solas BioVentures reposted this
Investor | Family Offices | Investment banking | Healthcare C-suite | Non exec. | Chairman | Global speaker
Very much looking forward to our panel discussion "Integrated Evidence Planning" at LSI Europe in London next week. I know many of you will attend the conference, I am looking forward to seeing you there. Thank you Joseph Ferrara for the moderation.
We’re excited to unveil another new panel for LSI Europe ‘25 — Integrated Evidence Planning: Building a Roadmap for Development and Commercial Success This panel will explore how companies can design evidence strategies that support both product approval and market adoption. With perspectives from strategy, investment, clinical development, regulation, and commercialization, the discussion will highlight what it takes to align stakeholders and build a roadmap that drives long-term success. In this session, you’ll hear from: • Joseph Ferrara — Chief Strategy Officer, Veranex • Laurent Pacheco, MD PhD MBA FFPM GFMD — Venture Partner, Solas BioVentures • Bill Niland — CEO, ReGelTec, Inc • Erin McEachren — Vice President & General Manager, Enabling Technologies: Cranial and Spinal Technologies, Medtronic • Jose Pablo Morales, MD — Former FDA • Shai Ran Sapir — Technology Development Manager - Cardiovascular Lead, Mayo Clinic Want to join us at LSI Europe ‘25? Registration is still open for a limited time. Register on our website today for your opportunity to connect with the industry's top decision-makers at LSI Europe ‘25 on September 7-11 in London. #LSIEurope25
-
-
Solas BioVentures reposted this
We’re excited to unveil another new panel for LSI Europe ‘25 — Pre-clinical Perspectives: Navigating the Investor and Regulatory Landscape Before First in Human Before a technology ever reaches patients, companies face critical questions: how much data is enough, what do investors need to see, and how do regulators view early-stage programs? This panel brings together voices from venture capital, pre-clinical services, regulatory, and the CEO seat to share how they approach the path to first-in-human studies. In this session, you’ll hear from: • Ryan Roberts — Chief Commercial Officer, Veranex • C David Adair MD, MBA, FACOG, FASH, C-EFM — Co-Founder, Managing Partner, Solas BioVentures • Nicolas Borenstein — Scientific Director, President of Preclinical Services, Veranex • Liam J. Burns — CEO, Qaelon Medical • Carine Schorochoff — CEO, Cardiawave • Jose Pablo Morales, MD — Former FDA Want to join us at LSI Europe ‘25? Registration is still open for a limited time. Register on our website today for your opportunity to connect with the industry's top decision-makers at LSI Europe ‘25 on September 7-11 in London. #LSIEurope25
-
-
Our team attending LSI Europe '25 is ready and excited to meet innovators and investors driving forward the change in healthcare that we need.
Solas BioVentures is a venture capital firm investing exclusively in the Life Science industry. With a strategic focus on early and development-stage companies, Solas BioVentures invests in biopharmaceuticals, medical devices, diagnostics, and digital health technologies. Their investment team combines decades of expertise spanning medical, biotechnology, operational, managerial, and financial disciplines, enabling them to identify and support innovative solutions that transform healthcare. Solas BioVentures takes a founder-centric approach, empowering life sciences visionaries to bring breakthrough medical innovations to market. The firm’s close collaboration with its limited partners, many of whom are medical professionals, allows them to incorporate clinical insights into their investment evaluations, ensuring a patient-focused approach to healthcare innovation. The company’s Emerging Healthcare Fund includes: • InterShunt Technologies, Inc. (LSI Alumni - Harlee Sorkin) • iO Urology Corp (Britton Garrett) • NX PRENATAL INC. (Paul Kortschak) • Stimdia Medical (LSI Alumni - Tim Miller) • Vektor Medical, Inc. (LSI Alumni - Robert J. Krummen) • among many others Join us in welcoming C David Adair MD, MBA, FACOG, FASH, C-EFM (Co-Founder & Managing Partner), Joshua Eckelberry (Principal), Laurent Pacheco, MD PhD MBA FFPM GFMD (Venture Partner), and Isaiah Reeves, PhD (Analyst) to LSI Europe ‘25 taking place September 7-11 in London. Want to join us at LSI Europe ‘25? The next price increase is August 15th. Register on our website today for your opportunity to connect with the industry's top decision-makers at LSI Europe ‘25 on September 7-11 in London.
-
-
Starting soon! Join Etienne Nichols 🎙️and Joshua Eckelberry talking about the who, what, why, and where Solas BioVentures decides to invest in the life sciences.
Happening tomorrow! Don’t miss a live taping of The Global Medical Device Podcast with Etienne Nichols of Greenlight Guru and Joshua Eckelberry from Solas BioVentures. They’ll unpack what MedTech investors are really looking for—plus the pitfalls to avoid and the trends you need to watch. 🎧 Tune in for real talk on funding success in MedTech. 📅 Save your spot: https://bit.ly/40FWyzY #MedTech #LifeSciences #VentureCapital #GreenlightGuru #MedicalDevice
-
-
Thank you LSI for the chance to moderate an important and timely topic. Why has all the risk takers disappeared and how to navigate this challenging environment for VC, start ups, as well as higher food chain partners. Always a great event of shared learnings and networking. On behalf of Solas BioVentures and myself we say thank you.
We’re excited to unveil another new panel for LSI Europe ‘25 — The Future of Early-Stage Medtech Investing: A Global Outlook As capital becomes more selective and funding climates vary across regions, early-stage medtech companies must adapt to a shifting investment landscape. This panel brings together seasoned investors from across Europe and the United States to discuss how they’re navigating the current landscape, where they see opportunity, and what founders need to know to stand out in today’s market. In this session, you’ll hear from: • C David Adair MD, MBA, FACOG, FASH, C-EFM — Managing Partner, Co-founder, Solas BioVentures • Bibi Sattar Marques — Partner, Buenavista Equity Partners (formerly GED Capital) • Branden Rosenhan MD — Founding Partner, MedMountain Ventures • Robert Hornby - Mercia Ventures — Investment Director, Mercia Ventures Want to join us at LSI Europe ‘25? Register on our website today for your opportunity to connect with the industry's top decision-makers at LSI Europe ‘25 on September 7-11 in London.
-
-
Listen and learn from a real green wave A. Travis Manasco, MD Travis is a rising star in our industry and he shares some great advice for the aspiring Bioentrepreneur. Well done Travis and thank you BIO from the BAYOU for hosting.
What are biotech investors really looking for? In the latest episode of #BIOfromtheBAYOU, host James Zanewicz, JD, LLM, RTTP, sits down with A. Travis Manasco, MD — Principal at Solas BioVentures and practicing ICU physician — to unpack the biotech pitch from an investor's perspective. 🎙 Learn about: • The "goat, moat, float, and dote" framework Solas uses to evaluate startups • How to create a focused, investor-ready pitch • Why building relationships with VCs is key to long-term success Listen now and sharpen your strategy before your next funding conversation. 🔗 https://lnkd.in/gfuR4paz #Biotech #VentureCapital #StartupFunding #LifeScience #BiotechStartups #TechTransfer #Innovation
-
Check out our Principal A. Travis Manasco, MD in this new podcast! In this episode of BIO from the BAYOU, host James Zanewicz, JD, LLM, RTTP, sits down with A. Travis Manasco, MD – Principal at Solas BioVentures, practicing Intensivist, and Tulane alumnus – for a clear-eyed look at what it takes to secure life science venture capital. From communicating clearly to avoiding common missteps, Travis offers practical advice every founder should hear before stepping into a pitch meeting.
Thank you to James Zanewicz, JD, LLM, RTTP and Ian McLachlan for having me on BIO from the BAYOU. We had a great conversation exploring: - The "Goat, Float, Moat, and DOTE" Solas BioVentures approach to evaluating investments - Crafting an investor-ready pitch that truly stands out - Why fierce focus matters - How practicing medicine powers my investment perspective Spotify: https://lnkd.in/eqRtBBec Apple: https://lnkd.in/eRFArgZg
-
Solas BioVentures reposted this
Solas BioVentures sends our collective team’s congratulations to the InterShunt Technologies, Inc. Team. Harlee Sorkin has led an incredible effort to build the only energy and implant free device, just like God designed the cardio vascular system, free of hardware and current. More importantly to build an incredibly talented team. It is great to see it start it’s first in human USA efforts. Well done Harlee and team.
CEO at InterShunt Technologies, Inc. & Clinical Assistant Professor at University of Illinois
🚨Milestone Alert‼️ The first patient has been enrolled in the EASE HF2 clinical trial marking the next leap forward for InterShunt Technologies, Inc. Thanks to the sure hands of Ramesh Emani and the well-oiled Interventional Cardiology team at The Christ Hospital Health Network for making this week possible. I'm grateful to work with an unflappable team who are on a mission to bring innovative heart failure solutions to life. ♥️
-